Professional Documents
Culture Documents
Journ 3
Journ 3
www.elsevierhealth.com/journals/jinf
KEYWORDS
Scabies;
Skin sores;
Impetigo;
Pyoderma;
Children;
Paediatrics
Introduction
Impetigo
Background
Impetigo is a common superficial skin infection which
predominantly affects young children.3,4 It is estimated
that more than 162 million children are suffering from
impetigo at any one time.2 The burden of disease is highest
in low-income countries and within marginalised populations in developed nations.2 Infection is caused by invasion
of the epidermis by bacteria colonising the skin following
* Corresponding author. Telethon Kids Institute, University of Western Australia, West Perth, Western Australia 6872, Australia.
Tel.: 61 894897777.
E-mail addresses: daniel.yeoh@health.wa.gov.au (D.K. Yeoh), Asha.Bowen@menzies.edu.au (A.C. Bowen), Jonathan.Carapetis@
telethonkids.org.au (J.R. Carapetis).
http://dx.doi.org/10.1016/j.jinf.2016.04.024
0163-4453/ 2016 Published by Elsevier Ltd on behalf of The British Infection Association.
S62
minor trauma. Autoinoculation is common and the infection
is highly transmissible. Hot and humid climatic conditions,
poor access to water and possibly overcrowding are factors
which play a role in frequent impetigo transmission in
endemic areas.4
The bacterial aetiology of impetigo varies according to
region and continues to change over time. In tropical
climates Streptococcus pyogenes (Group A Streptococcus
or GAS) remains the major pathogen3,4 and co-infection
with Staphylococcus aureus is common.5 In temperate climates S. aureus has largely replaced S. pyogenes as the
predominant pathogen in impetigo6 and community acquired methicillin resistant S. aureus (CA-MRSA) is of
increasing importance worldwide.6e8
Treatment
When determining impetigo treatment, there are several
important factors including the extent of disease, community wide prevalence, likely adherence to treatment and
known antimicrobial resistance. Most of the clinical trials
for impetigo treatment relate to limited or uncomplicated
impetigo, defined as fewer than 5 lesions. Where, impetigo
is extensive (greater than 5 lesions) or community prevalence is high, refer to the treatment section on extensive
impetigo.
Limited or uncomplicated impetigo
A Cochrane systematic review concluded that topical
antibiotics are the most effective treatment for limited
impetigo.23 This review included 68 randomised control trials representing 5578 participants,23 finding that mupirocin, fusidic acid and retapamulin were all superior to
placebo and there was no difference demonstrated between the most commonly studied topical agents: mupirocin and fusidic acid. In addition, there was no significant
difference found in 7-day cure rates between topical and
oral antibiotics (excluding erythromycin which is inferior
to topical mupirocin) and topical antibiotic use was associated with fewer adverse events.23 The review also cited a
lack of supportive evidence for the use of disinfectant solutions in the treatment of impetigo.23
There are several factors to consider when selecting a
topical antibiotic. Resistance to mupirocin and fusidic acid
among S. aureus isolates is increasing in association with
increased use of these agents.6,24 Although retapamulin
has demonstrated good in vitro activity against methicillin
resistant S. aureus (MRSA), its efficacy in clinical trials
against MRSA infections has been variable25,26 and it is
not approved for the treatment of MRSA infections. Moreover, S. aureus isolates with elevated minimum inhibitory
concentrations (MICs) to retapamulin have been described,
although the clinical significance of this is uncertain.27
There are calls to restrict the use of topical fusidic acid
in order to preserve the oral formulation as a useful agent,
in combination with rifampicin, for difficult-to-treat MRSA
infections.24 Topical fusidic acid is not available for use in
the USA and this is reflected in the Infectious Diseases Society of America (IDSA) guidelines for skin and soft tissue
infection which recommend topical retapamulin or mupirocin for uncomplicated impetigo.22
Extensive impetigo
Determining the optimal treatment of extensive impetigo,
particularly in resource-limited settings where the burden
of disease is highest, remains a challenge.4 It is generally
accepted that the use of systemic antibiotics for extensive
disease is practical and appropriate, yet there are limited
S63
Bacterial decolonisation may play a role in the management of patients with recurrent skin infections, the prevention of post-surgical infections and in hospital based
MRSA control,22,34,35 however the utility of decolonisation
in the prevention of impetigo on a community level is unclear. Recent randomised controlled trials in military cohorts
assessing
nasal
mupirocin36
and
topical
chlorhexidine37 respectively failed to demonstrate any
reduction in S. aureus skin and soft tissue infections. In
addition to the practical issues of implementing ongoing
topical decolonisation measures on a community level,
the widespread community use of mupirocin and/or chlorhexidine could result in the increased circulation of S.
aureus strains resistant to these agents and thus limit their
effectiveness.27,38,39 Recommendations for the use of
chemoprophylaxis to decolonise household contacts of
cases of invasive S. pyogenes disease vary and clear evidence of efficacy in preventing invasive disease is lacking.12,40 The role of broader community based S.
pyogenes decolonisation in the prevention of skin disease
has not been assessed.
It is clear that the greatest burden of impetigo and its
complications is borne by resource-limited populations,
where it is critical to focus on disease prevention. There
is ongoing work in the development of a vaccine against
GAS which could offer a cost-effective and practical avenue
for disease prevention, although a vaccine is not imminent.41 In the interim, advocacy to improve access to
health services, sanitation and housing and to reduce overcrowding in areas where impetigo is highly prevalent should
be a major focus in disease prevention. There is some evidence that greater access to swimming pools42,43 and a
combination of hand-washing and daily bathing44 can
reduce the burden of impetigo. On a broader scale, as evidenced in the industrialisation of Asian countries such as
Singapore, complications such as APSGN can be virtually
eliminated in the setting of improved socioeconomic status,
housing and health services.45
Scabies
Background
Scabies is an infection of the skin caused by the mite Sarcoptes scabiei var hominis. The adult mites burrow into
the epidermis and reproduce. In the epidermis, the mites
and their excreta produce a delayed hypersensitivity reaction which is responsible for the rash and pruritus associated
with
scabies
infestation.
Transmission
is
predominantly via prolonged skin-to-skin contact and
most commonly occurs between members of a household.46
Unsurprisingly scabies infection is associated with overcrowding and socioeconomic disadvantage4,46,47 and children carry the highest burden of disease.48 The
prevalence of scabies was found to range from 0.2% to
71.4% in a recent systematic review of population based
studies.48 The highest prevalence is seen in tropical regions, such as Central America, the Pacific islands and
Northern Australia.48 In developed countries prevalence is
generally low but outbreaks amongst populations in institutionalised care are well described.47
S64
Treatment
Individual treatment
There are various topical therapies utilised in the treatment of scabies. In a Cochrane review of randomised
control trials comparing scabies therapies, permethrin
was found to be the most effective topical therapy (superior to lindane and crotamiton).49 Benzyl benzoate is
another effective topical therapy that is preferred in
some resource-limited settings due to the relatively high
cost of permethrin, but is less well tolerated.46,54 The
Conclusions
The significant impact of scabies and impetigo on the
health of people in resource-limited settings has in the
past been under-recognised. Promisingly, there is growing
interest and advocacy concerning scabies and skin sores as
demonstrated by the recent formation of the International
Alliance for the Control of Scabies55 and the inclusion of
scabies on the WHO list of neglected tropical diseases in
2013. There is advocacy for impetigo to be included on
this list as well.2
There are safe and efficacious treatments available for
these common skin infections, yet in many areas where
disease burden is highest, little has changed with regards to
control. Ongoing research exploring risk factors and aetiology, improved methods for diagnosis and approaches to
both individual and community based treatment is
required. Arguably, addressing the environmental and socioeconomic factors which serve to perpetuate the high
rates of skin disease in certain communities is of chief
importance. Whilst in the industrialised world scabies and
impetigo are often considered trivial, ongoing efforts to
address the major impact of these infections in the
developing world remain extremely important.
Conflict of interest
The authors have no conflict of interest to declare.
References
S65
6. Bangert S, Levy M, Hebert AA. Bacterial resistance and impetigo treatment trends: a review. Pediatr Dermatol 2012;
29(3):243e8.
7. Tong SY, Varrone L, Chatfield MD, Beaman M, Giffard PM. Progressive increase in community-associated methicillin-resistant Staphylococcus aureus in Indigenous populations in
northern Australia from 1993 to 2012. Epidemiol Infect
2015;143(7):1519e23.
8. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler Jr VG.
Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015;28(3):603e61.
9. Koning S, Mohammedamin RS, van der Wouden JC, van Suijlekom-Smit LW, Schellevis FG, Thomas S. Impetigo: incidence
and treatment in Dutch general practice in 1987 and 2001 e
results from two national surveys. Br J Dermatol 2006;
154(2):239e43.
10. Bowen AC, Tong SY, Andrews RM, OMeara IM, McDonald MI,
Chatfield MD, et al. Short-course oral co-trimoxazole versus
intramuscular benzathine benzylpenicillin for impetigo in a
highly endemic region: an open-label, randomised, controlled,
non-inferiority trial. Lancet 2014;384(9960):2132e40.
11. Gear RJ, Carter JC, Carapetis JR, Baird R, Davis JS. Changes in
the clinical and epidemiological features of group A streptococcal bacteraemia in Australias Northern Territory. Trop
Med Int Health TM IH 2015;20(1):40e7.
12. Boyd R, Patel M, Currie BJ, Holt DC, Harris T, Krause V. High
burden of invasive group A streptococcal disease in the Northern Territory of Australia. Epidemiol Infect 2016;144(5):
1018e27.
13. Skull SA, Krause V, Coombs G, Pearman JW, Roberts LA. Investigation of a cluster of Staphylococcus aureus invasive infection in the top end of the Northern Territory. Aust N Z J
Med 1999;29(1):66e72.
14. Currie BJ, Carapetis JR. Skin infections and infestations in
Aboriginal communities in northern Australia. Australas J Dermatol 2000;41(3):139e43. quiz 44e5.
15. Marshall CS, Cheng AC, Markey PG, Towers RJ, Richardson LJ,
Fagan PK, et al. Acute post-streptococcal glomerulonephritis
in the Northern Territory of Australia: a review of 16 years
data and comparison with the literature. Am J Trop Med
Hyg 2011;85(4):703e10.
16. Hoy WE, White AV, Tipiloura B, Singh G, Sharma SK,
Bloomfield H, et al. The multideterminant model of renal disease in a remote Australian Aboriginal population in the
context of early life risk factors: lower birth weight, childhood post-streptococcal glomerulonephritis, and current
body mass index influence levels of albumi. Clin Nephrol
2015;83(7 Suppl. 1):75e81.
17. Hoy WE, White AV, Dowling A, Sharma SK, Bloomfield H,
Tipiloura BT, et al. Post-streptococcal glomerulonephritis is
a strong risk factor for chronic kidney disease in later life.
Kidney Int 2012;81(10):1026e32.
18. McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever:
a chink in the chain that links the heart to the throat? Lancet
Infect Dis 2004;4(4):240e5.
19. McDonald MI, Towers RJ, Andrews RM, Benger N, Currie BJ,
Carapetis JR. Low rates of streptococcal pharyngitis and
high rates of pyoderma in Australian aboriginal communities
where acute rheumatic fever is hyperendemic. Clin Infect
Dis e Off Publ Infect Dis Soc Am 2006;43(6):683e9.
20. Steer AC, Tikoduadua LV, Manalac EM, Colquhoun S,
Carapetis JR, Maclennan C. Validation of an Integrated Management of Childhood Illness algorithm for managing common
skin conditions in Fiji. Bull World Health Organ 2009;87(3):
173e9.
21. Project. East Arnhem regional healthy skin project e recognising and treating skin conditions. 2009.
S66
22. Stevens DL, Bisno AL, Chambers HF, Dellinger EP,
Goldstein EJ, Gorbach SL, et al. Practice guidelines for the
diagnosis and management of skin and soft tissue infections:
2014 update by the Infectious Diseases Society of America.
Clin Infect Dis e Off Publ Infect Dis Soc Am 2014;59(2):
e10e52.
23. Koning S, van der Sande R, Verhagen AP, van SuijlekomSmit LW, Morris AD, Butler CC, et al. Interventions for impetigo. Cochrane Database Syst Rev 2012;1:CD003261.
24. Howden BP, Grayson ML. Dumb and dumber e the potential
waste of a useful antistaphylococcal agent: emerging fusidic
acid resistance in Staphylococcus aureus. Clin Infect Dis e
Off Publ Infect Dis Soc Am 2006;42(3):394e400.
25. Tanus T, Scangarella-Oman NE, Dalessandro M, Li G,
Breton JJ, Tomayko JF. A randomized, double-blind, comparative study to assess the safety and efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of
secondarily infected traumatic lesions and impetigo due to
methicillin-resistant Staphylococcus aureus. Adv Skin Wound
Care 2014;27(12):548e59.
26. Yang LP, Keam SJ. Retapamulin: a review of its use in the
management of impetigo and other uncomplicated superficial
skin infections. Drugs 2008;68(6):855e73.
27. McNeil JC, Hulten KG, Kaplan SL, Mason EO. Decreased susceptibilities to Retapamulin, Mupirocin, and Chlorhexidine
among Staphylococcus aureus isolates causing skin and soft
tissue infections in otherwise healthy children. Antimicrob
Agents Chemother 2014;58(5):2878e83.
28. Miller LG, Daum RS, Creech CB, Young D, Downing MD,
Eells SJ, et al. Clindamycin versus trimethoprimsulfamethoxazole for uncomplicated skin infections. N Engl
J Med 2015;372(12):1093e103.
29. Bowen AC, Lilliebridge RA, Tong SY, Baird RW, Ward P,
McDonald MI, et al. Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole? J Clin Microbiol
2012;50(12):4067e72.
30. Faye O, Hay RJ, Diawara I, Mahe A. Oral amoxicillin vs. oral
erythromycin in the treatment of pyoderma in Bamako,
Mali: an open randomized trial. Int J Dermatol 2007;46(Suppl.
2):19e22.
31. Johnston F, Carapetis J, Patel MS, Wallace T, Spillane P. Evaluating the use of penicillin to control outbreaks of acute poststreptococcal glomerulonephritis. Pediatr Infect Dis J 1999;
18(4):327e32.
32. Carapetis JR, Connors C, Yarmirr D, Krause V, Currie BJ. Success of a scabies control program in an Australian aboriginal
community. Pediatr Infect Dis J 1997;16(5):494e9.
33. Lawrence G, Leafasia J, Sheridan J, Hills S, Wate J, Wate C,
et al. Control of scabies, skin sores and haematuria in children
in the Solomon Islands: another role for ivermectin. Bull
World Health Organ 2005;83(1):34e42.
34. Cookson B, Bonten MJ, Mackenzie FM, Skov RL, Verbrugh HA,
Tacconelli E. Meticillin-resistant Staphylococcus aureus
(MRSA): screening and decolonisation. Int J Antimicrob
Agents 2011;37(3):195e201.
35. Simor AE. Staphylococcal decolonisation: an effective strategy for prevention of infection? Lancet Infect Dis 2011;
11(12):952e62.
36. Ellis MW, Griffith ME, Dooley DP, McLean JC, Jorgensen JH,
Patterson JE, et al. Targeted intranasal mupirocin to prevent
colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a
cluster randomized controlled trial. Antimicrob Agents Chemother 2007;51(10):3591e8.
37. Whitman TJ, Herlihy RK, Schlett CD, Murray PR,
Grandits GA, Ganesan A, et al. Chlorhexidine-impregnated
cloths to prevent skin and soft-tissue infection in Marine recruits: a cluster-randomized, double-blind, controlled
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
S67
61.
62.
63.
64.